Recombinant factor VIIa
Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients
... coagulation factor concentrates ineffective, and alternative means must be used to achieve ...hemostasis. Recombinant factor VIIa (rFVIIa) was developed to control bleed- ing episodes in ...
11
Overview of the use of recombinant factor VIIa in children
... prothrombin complex concentrate (aPCC) is produced from pooled, donated, virally inactivated plasma, and contains activated factors II, VII, IX, and X. The other bypassing agent is recombinant factor ...
8
An in vitro evaluation of standard rotational thromboelastography in monitoring of effects of recombinant factor VIIa on coagulopathy induced by hydroxy ethyl starch
... 25. Poon MC, d'Oiron R, Hann I, Negrier C, de Lumley L, Thomas A, Karafoulidou A, Demers C, Street A, Huth-Kuhne A, Petrini P, Fressi- naud E, Morfini M, Tengborn L, Marques-Verdier A, Musso R, Deve- cioglu O, Houston ...
6
Cost effectiveness of recombinant factor VIIa for treatment of intracerebral hemorrhage
... Recombinant factor VIIa (rFVIIa) is currently FDA- approved for the treatment of patients with hemophilia. Given its thrombogenic effects, it was hypothesized that it might be useful for limiting ...
9
Pediatric Off-label Use of Recombinant Factor VIIa
... received recombinant factor VIIa for off- label ...receiving recombinant factor VIIa were disseminated intravascular coagulation/sepsis (28), surgical bleeding (19), proce- dural ...
9
The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor
... via Factor VIIa-dependent activation of Factor X, but direct proof has not been available for the participation of tissue factor in this ...of recombinant Factor VIIa ...
7
Use of Recombinant Factor VIIa in Obstetrics
... Transfusion of blood and blood products is regarded as unacceptable, while rFVIIa a synthetic agent, remains an acceptable treatment to many Jehovah’s witnesses. A case report on successful treatment of postpartum ...
14
Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings
... of recombinant activated factor VII (rFVIIa) are established in patients with inherited or acquired hemophilia with inhibitors and in patients with congenital factor VII ...
8
Current difficulties and recent advances in bypass therapy for the management of hemophilia with inhibitors: a new and practical formulation of recombinant factor VIIa
... Stability at room temperature for this product was achieved through the addition of 2 new excipients to the lyophilized powder – a stabilizer (sucrose) and an antioxidant (methionine) – and by the use of a diluent ...
8
Comparison of 3-Factor Prothrombin Complex Concentrate and Low-Dose Recombinant Factor VIIa for Warfarin Reversal
... To compare the effects of rFVIIa and PCC on anticoagu- lation reversal, Dickneite administered saline, 100 mcg/kg rFVIIa, or PCC 50 units/kg (Beriplex® P/N-a 4 factor PCC) in rats anticoagulated with either one ...
7
Failure of recombinant factor VIIa in a patient with severe polymicrobial sepsis and postoperative uncontrolled intraabdominal bleeding
... of factor VII or VIIa in plasma after the administration of rFVIIa only proves the exist- ence of factor VII and its successful administration, but it does not predict any effect on haemostasis ...
6
Thromboembolic risks of recombinant factor VIIa Use in warfarin-associated intracranial hemorrhage: a case–control study
... activated factor capable of direct binding to tissue factor suggest it may achieve faster hemostasis, PCC contains all vitamin-K dependent coagulation factors and may be a more efficacious agent for ...
7
Recombinant factor VIIa for uncontrollable bleeding in patients with extracorporeal membrane oxygenation: report on 15 cases and literature review
... Logan et al. [32] recently evaluated off-label rFVIIa use in patients with intractable bleeding (2000 to 2008) and found that, in US hospitals, its use increased > 140- fold, so that in 2008, 97% of in-hospital ...
10
Intrapulmonary Recombinant Factor VIIa for Diffuse Alveolar Hemorrhage in Children
... Recently, adult studies have reported the successful use of intrapulmonary rFVIIa for DAH. Even in severe macroscopic pulmonary bleeding, patients have been shown to respond rapidly. These effects are due to combined ...
7
The utility of recombinant factor VIIa as a last resort in trauma
... Over the last decade, rFVIIa has been explored as a potential treatment for many coagulopathic states other than congenital conditions and hemophilias [7,11,24] . Theoretically, rFVIIa seems to be an appealing option ...
6
Off-Label Use of Recombinant Factor VIIa in Pediatric Patients
... WHAT THIS STUDY ADDS: This is the largest reported case series of off-label rFVIIa in pediatric patients from a well-designed, representative, and rigorously audited registry of rFVIIa u[r] ...
10
Critical appraisal of the role of recombinant activated factor VII in the treatment of hemophilia patients with inhibitors
... therapy. Recombinant factor VIIa is selected due to the awareness of the anamnestic response provoked by residual factor VIII antigen contained in ...
12
Thrombin generation during cardiopulmonary bypass: the possible role of retransfusion of blood aspirated from the surgical field
... Germany). Factor VIIa levels were determined by a specific immunoassay, which has been described else- where ...of factor VII exposed following its activation by cleavage at Arg152- ...
9
Inhibitor of the factor VIIa tissue factor complex is reduced in patients with disseminated intravascular coagulation but not in patients with severe hepatocellular disease
... Inhibition of Factor VIIa-tissue factor activity by a plasma component(s) that requires factor Xa has been described recently. In this communication, we have developed a specific radiometric ...
6
Tissue factor expression by endothelial cells in sickle cell anemia
... Willebrand factor and thrombomodu- lin, and they express flt-1 and KDR, receptors for the endothelial- specific mitogen ...MN). Recombinant Factors VIIa and X and mAbs to TF and to Factor ...
7